Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of Rodatristat Ethyl in Healthy Japanese and Caucasian Subjects
NCT05065359Phase 1Completed
- Sponsor
- Altavant Sciences
- Start
- Oct 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rodatristat in pulmonary arterial hypertension (PAH) (8 arms), sponsored by Altavant Sciences. Primary endpoint: Incidence of adverse events at 21 days. Started Oct 2021; status: completed.
02
Drugs
rodatristat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT05065359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05065359.